16.2 Regulatory Agencies & Healthcare Accreditation (AABB, CLIA, DHS, OSHA, TJC)

16.2 Regulatory Agencies & Healthcare Accreditation (AABB, CLIA, DHS, OSHA, TJC)

Anesthesia technology practice is embedded within a stringent web of federal statutes, national clinical standards, and accreditation mandates designed to protect patients from medical errors and protect healthcare workers from occupational hazards. The ASATT content outline names five bodies whose functions candidates should know: the Association for the Advancement of Blood & Biotherapies (AABB), the Clinical Laboratory Improvement Amendments (CLIA) program, the state Department of Health Services (DHS), the Occupational Safety and Health Administration (OSHA), and The Joint Commission (TJC). Federal and state regulations are legally binding, while accreditation standards such as those of TJC and AABB are enforced through accreditation surveys and facility policy.

---

The Regulatory Matrix in Perioperative Technology

+-----------------------------------------------------------------------------------------+
|                         PERIOPERATIVE REGULATORY & ACCREDITATION MATRIX                 |
+-------------------+--------------------+------------------------+-----------------------+
| Agency / Body     | Regulatory Domain  | Anesthesia Technology  | Key Mandatory Rules   |
|                   |                    | Clinical Focus         | & Parameters          |
+-------------------+--------------------+------------------------+-----------------------+
| AABB              | Blood banking,     | Autologous cell        | Label with 2 IDs,     |
| (Advancement of   | transfusion, and   | salvage operation,     | 'For Autologous Use   |
| Blood &           | autologous blood   | anticoagulation,       | Only'; 4-hr RT limit, |
| Biotherapies)     | processing         | washing, reinfusion    | 24-hr 1-6°C limit.    |
+-------------------+--------------------+------------------------+-----------------------+
| CLIA              | Clinical laboratory| Point-of-Care Testing  | Daily 2-level liquid  |
| (Clinical Lab     | diagnostic testing | (POCT): ACT, blood gas | QC, annual competency |
| Improvement       | and accuracy       | co-oximetry, glucose,  | calibration check,    |
| Amendments)       | standards          | thromboelastography    | PT or alternative.    |
+-------------------+--------------------+------------------------+-----------------------+
| OSHA              | Occupational       | Bloodborne Pathogens   | Point-of-use sharps,  |
| (Occupational     | safety and worker  | Standard, engineering  | no two-hand recapping,|
| Safety & Health   | health protection  | controls, needle-safe, | Hep B offer in 10 days|
| Administration)   |                    | PEP, HazCom, WAG       | NIOSH WAG RELs.       |
+-------------------+--------------------+------------------------+-----------------------+
| DHS               | State health       | Facility licensure,    | State licensing and   |
| (State Dept. of   | department:        | inspections, complaint | survey rules; agency  |
| Health Services)  | licensing and      | investigations, CMS    | names vary by state.  |
|                   | inspection         | and CLIA surveys       |                       |
+-------------------+--------------------+------------------------+-----------------------+
| TJC               | Healthcare facility| National Patient Safety| 2 patient identifiers,|
| (The Joint        | quality, safety,   | Goals (NPSGs), Time-Out| Universal Protocol,   |
| Commission)       | and accreditation  | medication labeling on | label all basins/pens,|
|                   |                    | all field syringes     | alarm management.     |
+-------------------+--------------------+------------------------+-----------------------+

---

AABB Standards: Intraoperative Cell Salvage & Autologous Blood Recovery

The Association for the Advancement of Blood & Biotherapies (AABB) establishes international clinical standards governing blood collection, processing, component therapy, and autologous transfusion. Intraoperative cell salvage—recovering blood shed during surgery, washing out impurities, and concentrating viable red cells for autotransfusion—falls directly under AABB clinical jurisdiction.

Anticoagulation Principles & Aspiration Setup

During surgical aspiration of shed blood, the technologist must prevent clotting within the suction reservoir while avoiding excessive anticoagulation that could trigger systemic coagulopathy upon reinfusion.

• Anticoagulant Solutions: Standard solutions include Anticoagulant Citrate Dextrose Solution A (ACD-A) or heparinized saline (commonly about 30,000 units of heparin per 1,000 mL of 0.9% saline).
• Titration Ratio: A common target is about 15 mL of anticoagulant for every 100 mL of aspirated blood (roughly 1:7), adjusted to the device instructions. In cases of rapid hemorrhage, the drip rate is accelerated to match blood collection.
• Suction Vacuum Control: Suction is kept low, commonly at or below about 150 mmHg of vacuum per device instructions. Higher vacuum creates shear stress that lyses fragile erythrocytes, elevating free plasma hemoglobin and reducing salvaged red cell yield.

Centrifugal Washing & Quality Parameters

Inside the cell salvage centrifuge bowl (e.g., Latham bowl), centrifugal force separates cellular elements based on specific gravity. Red blood cells (densest) pack against the outer bowl wall, while supernatant plasma, cellular debris, free hemoglobin, and anticoagulant are displaced inward and vented to a waste bag. The red cell pack is then washed with 0.9% normal saline (volume set by the device and the case, commonly about 1,000 mL or more per bowl) until the effluent runs clear.

• Quality Profile: A properly processed autologous unit commonly has a hematocrit of about 50% to 65%, with most free hemoglobin, heparin, activated clotting factors, and plasma potassium washed out.

Mandatory AABB Product Labeling Standards

AABB perioperative standards require traceable labeling of every salvaged unit. Facility policy sets the exact label format, which typically includes:

1. Patient's Full Legal Name
2. A Second Patient Identifier (such as medical record number or date of birth; never a room or bed number)
3. Date and Time of Collection or Processing
4. Prominent Conspicuous Statement: "FOR AUTOLOGOUS USE ONLY"
5. Expiration Date and Expiration Time
6. Identification / Initials of the Technologist or Operator

Storage Temperature & Reinfusion Timeline Protocols

Because autologous shed blood is collected from an open surgical cavity and contains no chemical preservatives or bacteriostatic agents, bacterial proliferation accelerates over time. AABB standards mandate strict shelf-life limitations:

+-----------------------------------------------------------------------------------------+
|                       AABB STORAGE & REINFUSION TIMELINE LIMITS                         |
+---------------------+-----------------------------+-------------------------------------+
| Storage Environment | Temperature Range           | Mandatory Expiration Limit          |
+---------------------+-----------------------------+-------------------------------------+
| Room Temperature    | Room temperature            | Must complete reinfusion within     |
|                     |                             | FOUR (4) HOURS of process completion|
+---------------------+-----------------------------+-------------------------------------+
| Refrigerated        | 1°C to 6°C (34°F to 43°F)   | Must complete reinfusion within     |
| (Blood Bank Monitored)                            | TWENTY-FOUR (24) HOURS              |
+---------------------+-----------------------------+-------------------------------------+

• The 4-Hour Room Temperature Rule: If the processed unit stays at room temperature, infusion must be completed within 4 hours of the end of processing. Blood not infused by then is discarded.
• The 24-Hour Refrigerated Rule: If infusion will be delayed, the labeled unit can be stored at 1°C to 6°C, provided storage begins within 4 hours of the end of processing; infusion must then be completed within 24 hours of the end of processing. Storage uses a monitored blood refrigerator per facility policy, not an ordinary unmonitored refrigerator.

---

CLIA Regulations & Perioperative Point-of-Care Testing (POCT)

The Clinical Laboratory Improvement Amendments of 1988 (CLIA), administered by the Centers for Medicare & Medicaid Services (CMS), the FDA, and the CDC, govern all clinical diagnostic testing performed on human specimens. Point-of-Care Testing (POCT) in surgical suites allows instantaneous evaluation of critical physiologic parameters.

CLIA Test Complexity Categorization

Under CLIA, tests are categorized into three levels of regulatory complexity based on technical skill, methodology, and risk of erroneous results:

1. Waived Tests: Simple tests with a low risk of erroneous results, such as FDA-cleared home-use tests and other tests the FDA has waived (e.g., bedside capillary blood glucose meters, urine pregnancy tests). Requires a CLIA Certificate of Waiver and following manufacturer instructions.
2. Moderate-Complexity Tests: Many intraoperative POCT systems (each test system's category is listed in the FDA CLIA database):
   • Activated Clotting Time (ACT): Hemochron, Medtronic ACT Plus (vital for heparin titration during cardiopulmonary bypass and vascular clamping).
   • Arterial and Venous Blood Gas (ABG) Analyzers: i-STAT, Radiometer ABL90, GEM Premier 5000 (measuring pH, PaCO₂, PaO₂, electrolytes, lactate, base excess).
   • Co-Oximetry Modules: Fractional oxyhemoglobin, carboxyhemoglobin, methemoglobin.
3. High-Complexity Tests: Methods that need more operator skill and judgment; some manual viscoelastic assays that require pipetting fall here, while newer cartridge-based systems may be categorized differently.

Mandatory Quality Control (QC) Protocols

For all moderate- and high-complexity instruments, CLIA mandates strict quality control verification:

• External Controls: Unless the laboratory follows an approved Individualized Quality Control Plan (IQCP), CLIA generally requires two levels of external control material each day of patient testing, with more frequent rules for some specialties (for example, coagulation and blood gas testing have 8-hour control requirements). For ACT systems, this means normal and prolonged clotting controls.
• New Reagent / Cartridge Lots: Liquid QC must be run whenever a new lot number or new shipment of cartridges, cuvettes, or reagents is opened, even if daily QC was already performed.
• Electronic Simulator Checks vs. Liquid QC: Modern cartridges (e.g., i-STAT) utilize internal electronic simulators that verify instrument circuitry and electrical zero points. Internal electronic checks do not replace external liquid QC unless an approved IQCP supports a reduced frequency, because electronic simulators cannot detect degraded electrochemical sensors, expired enzymes, or dried microfluidic reagent channels.

Calibration Verification, Proficiency Testing & Operator Competency

• Calibration Verification: Must be performed at least every 6 months or whenever major maintenance occurs, verifying assay linearity across low, mid, and high measurement ranges.
• Proficiency Testing (PT): For CLIA-regulated analytes, the laboratory enrolls in an approved PT program (e.g., College of American Pathologists [CAP]) with three testing events per year, testing samples like patient specimens without sharing results with other laboratories. For tests without required PT, the laboratory verifies accuracy at least twice a year by another method.
• Operator Competency: For non-waived testing, competency is assessed twice during the first year and annually after that, using six elements: direct observation of routine testing (including specimen handling), monitoring of result recording and reporting, review of worksheets, QC, and maintenance records, direct observation of maintenance and function checks, testing previously analyzed or blind specimens, and assessment of problem-solving skills.

---

DHS: State Department of Health Services

In the ASATT outline, DHS refers to the state Department of Health Services, the state health agency that regulates health care facilities. Names vary by state (for example, Department of Health, Department of Public Health, or Department of Health and Human Services), but the functions are similar:

• Facility licensure: Licenses hospitals, ambulatory surgery centers, and other health care facilities under state law, and inspects them for compliance with state rules.
• Complaint and incident investigations: Investigates complaints and, in many states, required reports of serious adverse events.
• Medicare certification surveys: Serves as the state survey agency for the Centers for Medicare & Medicaid Services (CMS), surveying facilities for Medicare participation and investigating complaints.
• CLIA inspections: Under agreement with CMS, state agencies inspect and certify clinical laboratories, including point-of-care testing sites. New York and Washington run their own CMS-approved laboratory programs.
• Public health reporting: Receives reports of certain communicable diseases and oversees state rules that affect infection control.

For the technologist, DHS rules shape equipment maintenance records, laboratory testing documentation, infection control practices, and readiness for unannounced state inspections.

---

OSHA Standards: Bloodborne Pathogens & Hazard Communication

The Occupational Safety and Health Administration (OSHA) enforces federal workplace standards protecting healthcare personnel from physical, biological, and chemical hazards.

Bloodborne Pathogens Standard (29 CFR 1910.1030)

Enacted to protect workers from occupational exposure to human immunodeficiency virus (HIV), Hepatitis B virus (HBV), and Hepatitis C virus (HCV).

1. Engineering Controls: Primary defense mechanisms that isolate or remove bloodborne hazards from the workplace:
   • Point-of-Use Sharps Containers: Rigid, puncture-resistant, leak-proof, color-coded red biohazard containers located immediately at the point of sharps use (placed within easy reach). Containers are replaced before they overfill, at the manufacturer's fill line (commonly about three-quarters full).
   • Needleless Systems & Safety Devices: Self-sheathing IV cannulas, retractable hypodermic needles, and blunt-fill needles for medication aspiration.
2. Work Practice Controls: Prohibitions on dangerous behaviors:
   • Strict Prohibition of Two-Handed Recapping: Contaminated needles must NEVER be recapped using a two-handed technique. Needles must never be bent, sheared, or manually broken. If recapping is unavoidable, personnel must utilize a single-handed "scoop" technique or a mechanical recapping device.
3. Mandatory Hepatitis B Vaccination Offer: Employers must offer the complete Hepatitis B vaccination series to all employees with potential occupational blood/body fluid exposure free of charge within 10 working days of initial job assignment. An employee who declines must sign an official OSHA declination statement, but retains the right to receive the vaccine at a later date at employer expense.

Post-Exposure Prophylaxis (PEP) Protocol for Sharps Injuries

When an accidental needlestick or mucocutaneous blood exposure occurs:

1. Immediate First Aid: Wash the wound with soap and water, and flush exposed mucous membranes with water (eyes with water or saline). Do not squeeze the wound or apply caustic agents such as bleach.
2. Immediate Reporting: Report the event immediately to the charge supervisor and occupational health.
3. Source Patient & Employee Testing: Obtain rapid serologic testing from the source patient (HIV antibody/antigen, HBsAg, anti-HCV) and baseline serology from the exposed employee with consent.
4. Post-Exposure Prophylaxis (PEP) Initiation: If the source is HIV-positive or high-risk unknown, start antiretroviral PEP as soon as possible, ideally within hours of exposure (it is generally not started after 72 hours), and continue it for 28 days with expert follow-up.

Hazard Communication (29 CFR 1910.1200) & Waste Anesthetic Gases (WAG)

• Safety Data Sheets (SDS): OSHA mandates that standardized 16-section Safety Data Sheets be immediately accessible 24/7 to all staff for every chemical present in the department (e.g., glutaraldehyde, OPA, desflurane, sevoflurane, soda lime).
• Waste Anesthetic Gases (WAG): Some studies have linked chronic exposure to reproductive and other health effects. OSHA has no specific exposure limit for anesthetic gases, but its guidance refers to the National Institute for Occupational Safety and Health (NIOSH) Recommended Exposure Limits (RELs), set in 1977:
  • Halogenated Agents Used Alone: 2 ppm ceiling (sampling period of no more than 1 hour).
  • Halogenated Agents Used With Nitrous Oxide: 0.5 ppm for the halogenated agent, plus 25 ppm nitrous oxide as a time-weighted average during anesthetic administration.
  • Technologists must inspect active scavenger interfaces, verify transfer tubing integrity, and perform periodic leak tests on anesthesia machines.

---

The Joint Commission (TJC) & National Patient Safety Goals (NPSGs)

The Joint Commission (TJC) accredits over 22,000 healthcare organizations across the United States. Its National Patient Safety Goals (NPSGs) address critical systemic failure modes in surgical environments.

NPSG 01.01.01: Two Patient Identifiers

Healthcare personnel must verify at least two unique patient identifiers prior to administering medications, drawing laboratory specimens, initiating blood transfusions, or performing invasive procedures. Valid identifiers include:

• Patient Full Legal Name
• Hospital Medical Record Number (MRN)
• Date of Birth (DOB)

Never Acceptable: The patient's room number, bed assignment, or geographical location can never be utilized as an identifier.

The Universal Protocol for Preventing Wrong Site, Wrong Procedure, Wrong Person Surgery

1. Pre-Procedure Verification Process: Ongoing verification of all pertinent documentation, signed operative consents, diagnostic imaging, and planned implants from admission through OR entry.
2. Surgical Site Marking: When a procedure involves laterality, multiple structures, or levels, the site is marked by the practitioner performing the procedure (or a permitted designee under TJC rules) with a mark that stays visible after prepping and draping.
3. The Intraoperative Time-Out: Conducted immediately prior to surgical incision or regional nerve block needle insertion:
   • Other activities are suspended to the extent possible so the team can focus.
   • Active verbal participation by every member of the multidisciplinary team (surgeon, anesthesiologist/CRNA, circulating RN, scrub tech, anesthesia technologist).
   • At minimum, the team confirms the correct patient, correct site, and correct procedure; many facilities add items such as positioning, antibiotic timing, implants, and equipment availability.

NPSG 03.04.01: Perioperative Medication Labeling Mandates

Medication errors in anesthesia suites frequently involve syringe swaps and mislabeled solution basins. TJC strictly enforces:

• Immediate Labeling Rule: Any medication or solution removed from its original manufacturer container into a secondary vessel (syringes, medicine cups, irrigation basins) must be immediately labeled if not administered instantaneously.
• Mandatory Label Information:
  1. Drug Name
  2. Strength / Concentration (e.g., Phenylephrine 100 mcg/mL)
  3. Total Amount or Volume (if not apparent from syringe markings)
  4. Expiration date when not used within 24 hours, and expiration time when expiration occurs in less than 24 hours
  5. Diluent Name and Volume (if not apparent from the container)
  6. Preparer's initials, which many facilities also require
• Syringe labels commonly follow ASTM D4774 user-applied label colors (e.g., yellow for induction agents, blue for opioids, fluorescent red for neuromuscular blockers, violet for vasopressors).

NPSG 06.01.01: Clinical Alarm Safety

Clinical alarm fatigue occurs when staff become desensitized to constant acoustic alarm chirps, leading to delayed responses to life-threatening apnea or arrhythmia alarms. TJC requires hospitals to make clinical alarm safety a priority, identify the most important alarms, and set policies for alarm settings and for who may silence or change them. Technologists should never silence or disable alarms outside those policies.